Luminex Corporation Announces First Commercial Shipment of FLEXMAP 3D Systems
Product News Nov 17, 2008
Luminex Corporation has announced the commercial sale and shipment of the first FLEXMAPTM 3D system manufactured in Austin, Texas. Full market release of the instrument is expected in the first quarter of 2009.
“We are very excited to announce our first commercial shipment of FLEXMAP 3D,” said Douglas Bryant, Executive Vice President and Chief Operating Officer of Luminex. “The increased speed, increased multiplexing capabilities, as well as the improved workflow of the instrument will offer researchers and clinicians rapid and accurate results to improve the health and well-being of people around the world.”
The FLEXMAP 3D system will offer medium and high volume laboratories improved analytical performance, greater speed, front end automation, enhanced throughput and higher multiplexing capabilities.
The FLEXMAP 3D system measures up to 500 analytes in a single well, as compared to the company’s current Luminex 200 system, which measures 100 analytes per well. Powered by xPONENT® 4.0 software, the system’s interface will benefit users with a simplified and optimized workflow.
The FLEXMAP 3D system utilizes Luminex’s flexible xMAP® Technology, which is built on the existing, technology of flow cytometry, microspheres, lasers, digital signal processing and traditional chemistry.
xMAP Technology can provides both protein and nucleic acid applications on one platform, and has allowed Luminex to expand its reach into market segments such as life science research, molecular diagnostics, HLA testing, and markets as diverse as biodefense, animal health and agro-biotech.